Nuclear export inhibitors with anti-tumoral and anti-viral activity

Regulated nucleo-cytoplasmic transport of pathobiologically relevant proteins is critical for tumor development and viral diseases. Transport is mediated by nuclear export signals (NESs) interacting with the export receptor CRM1. NESs have been identified in numerous disease relevant cellular and viral proteins. Hence, the pharmacogenetic interference with nuclear export provides an attractive and novel therapeutic principle to rationally control and target the activity of such disease factors. This invention now provides three novel nuclear export inhibitors (NEIs) with shown anti-tumoral and antiviral activity. As such, these drugs may represent a hitherto neglected additional pillar for combination treatment of human diseases.

Further Information: PDF

IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-50

Contact
Dr. Klaus Kobek

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Breakthrough in magnetism that could transform quantum computing and superconductors

Researchers discover new magnetic and electronic properties in kagome magnet thin films. A discovery by Rice University physicists and collaborators is unlocking a new understanding of magnetism and electronic interactions…

NASA to launch innovative solar coronagraph to Space Station

NASA’s Coronal Diagnostic Experiment (CODEX) is ready to launch to the International Space Station to reveal new details about the solar wind including its origin and its evolution. Launching in…

Boosting efficiency in mining with AI and automation

“Doing instead of procrastinating”. This is the AI strategy presented by Prof. Constantin Haefner, Director of the Fraunhofer Institute for Laser Technology ILT, at the “AKL’24 – International Laser Technology…